Medical Journal of the Islamic Republic Of Iran
مجله پزشکی جمهوری اسلامی ایران
Med J Islam Repub Iran
Medical Sciences
http://mjiri.iums.ac.ir
2
journal2
1016-1430
2251-6840
8
10.18869/mjiri
14
8888
13
en
jalali
1384
5
1
gregorian
2005
8
1
19
2
online
1
fulltext
en
A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY OF KETOCONAZOLE FOR REDUCING THE RISK OF OVARIAN HYPERSTIMULATION SYNDROME
Gynecology & Obstetrics
Gynecology & Obstetrics
Original Research
Original Research
<font face="Times New Roman" size="3"> </font><p class="MsoNormal" style="margin: 0in 0in 10pt text-align: justify"><b><font size="3"><font face="Calibri">ABSTRACT<o:p /></font></font></b></p><font face="Times New Roman" size="3"> </font><p class="MsoNormal" style="margin: 0in 0in 10pt text-align: justify"><font face="Calibri"><font size="3"><b>Background: </b>In order to
evaluate the role ofketoconazole in the prevention of ovarian hyperstimulation
syndrome (OHSS) in women with polycystic ovary syndrome (PCOS) undergoing
ovarian stimulation with gonadotropins, a prospective, randomized, double-blind,
placebo controlled study was done on one-hundred and nine PCOS women that had
been refeiTed to be treated by gonadotropins.<o:p /></font></font></p><font face="Times New Roman" size="3"> </font><p class="MsoNormal" style="margin: 0in 0in 10pt text-align: justify"><font face="Calibri"><font size="3"><b>Methods:</b> Alll09 women were
assigned for random allocation. Group A (50 patients) received two ampoules
ofhMG beginning on day 2 or 3 of the cycle and ketoconazole (50 mg/every 48
hours) starting on the first day ofhMG treatment. Group B (51 patients)
received the same protocol ofhMG combined with one tablet of placebo every 48
hours. Main outcome measures were follicular development, E2levels, and
pregnancy rate.<o:p /></font></font></p><font face="Times New Roman" size="3"> </font><p class="MsoNormal" style="margin: 0in 0in 10pt text-align: justify"><font face="Calibri"><font size="3"><b>Results:</b> The total number
ofhMG ampoules and duration oftreatment to attain ovarian stimulation was
higher in group A (p<O.OOO 1 ). Serum E2level and number of patients with
dominant follicles on day 9 of the cycle were higher in group B (p<O.OOO 1
). There was no significant difference between semm E2level and total number of
follicles at the time ofhCG administration in the two groups. The cancellation
rate and OHSS rate were similar in the two groups.<o:p /></font></font></p><font face="Times New Roman" size="3"> </font><p class="MsoNormal" style="margin: 0in 0in 10pt text-align: justify"><font size="3"><font face="Calibri"><b>Conclusion:</b> Ketoconazole
has no effect in prevention of OHSS in PCOS patients undergoing ovarian
stimulation. It may however reduce the rate of folliculogenesis and
steroidogenesis.<o:p /></font></font></p><font face="Times New Roman" size="3"> </font>
Polycystic ovary syndrome. ovarian hyperstimulation syndrome, ketoconazole.
153
158
http://mjiri.iums.ac.ir/browse.php?a_code=A-10-1-307&slc_lang=en&sid=1
MOHAMMAD EBRAHIM
PARSANEZHAD
parsame@sums.ac. ir
20031947532846003036
20031947532846003036
Yes
Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
MAHNAZ
PAKNIAT
20031947532846003037
20031947532846003037
No
Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
SAEED
ALBORZI
20031947532846003038
20031947532846003038
No
Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
ERNST HEINRICH
SCHMIDT
20031947532846003039
20031947532846003039
No
Department of Obstetrics and Gynecology, Evang Diakrmie Teaching Hospital of the Gottingen University, Bremen, Germany.